enGene issues EX-99.1 corporate presentation
The company distributed an investor presentation outlining views on its non-viral genetic medicine pipeline, specifically detailing findings on its market research, commercialization strategy, and the anticipated regulatory pathway for its product candidate detalimogene.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed